Algernon Pharmaceuticals Finding New Uses for Safe, Older Drugs
Christopher Moreau, CEO of UF startup Algernon Pharmaceuticals, Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, sat down with Proactive‘s Steve Darling at the 12th annual LD Micro Conference in Bel Air, California. The Vancouver, British Columbia-based company, is advancing its lead compounds for non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, and idiopathic pulmonary fibrosis.
Learn more about Algernon Pharmaceuticals Finding New Uses for Safe, Older Drugs.